Relevant bibliographies by topics / Survival endpoint

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Survival endpoint'

Author: Grafiati
Published: 9 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Survival endpoint.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Survival endpoint"

1

Bensimon, Gilbert. "Survival endpoint: Pro." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (2002): S35—S36. http://dx.doi.org/10.1080/146608202320374237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rosenfeld, Jeffrey. "Survival endpoint: Con." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (2002): S37—S39. http://dx.doi.org/10.1080/146608202320374246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Meininger, Vincent. "Survival endpoint: Summary." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 3, sup1 (2002): S41—S44. http://dx.doi.org/10.1080/146608202320374255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Teuwen, Laure-Anne Marie Nicole, Joanna Alyse Young, Maria Teresa Bourlon, Eva Segelov, and Hans Prenen. "Endpoints reported in phase 3 randomized clinical trials at ASCO 2022." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1570. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1570.

Full text
Abstract:
1570 Background: The goal of phase 3 randomized clinical trials (RCTs) is to show clinically meaningful benefit for patients. An analysis of phase 3 RCTs presented at the ASCO 2022 Annual Meeting (ASCO22) was undertaken to assess which endpoints were evaluated. Methods: A systematic analysis was undertaken of ASCO22 abstracts from phase 3 RCTs reporting primary, secondary, interim, updated, and subgroup analyses, as well as trials reporting methodology of currently enrolling studies. Trials that reported posthoc, exploratory, biomarker, and retrospective analyses of RCTs were excluded. Informa
APA, Harvard, Vancouver, ISO, and other styles
5

Hahn, Andreas, Andreas Podbielski, Markus M. Heimesaat, Hagen Frickmann, and Philipp Warnke. "Binary surrogate endpoints in clinical trials from the perspective of case definitions." European Journal of Microbiology and Immunology 11, no. 1 (2021): 18–22. http://dx.doi.org/10.1556/1886.2020.00031.

Full text
Abstract:
AbstractIntroductionSurrogate endpoints are widely used in clinical trials, especially in situations where the endpoint of interest is not directly observable or to avoid long trial periods. A typical example for this case is frequently found in clinical trials in oncology, where overall survival (OS) as endpoint of interest and progression free survival (PFS) as surrogate endpoint are discriminated.MethodsBased on the perspective of case definitions on surrogate endpoints, we provide a formal definition of such endpoints followed by a description of the structure of surrogate endpoints.Result
APA, Harvard, Vancouver, ISO, and other styles
6

Schmidt, Rene. "INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints." Neuro-Oncology 24, Supplement_1 (2022): i187. http://dx.doi.org/10.1093/neuonc/noac079.700.

Full text
Abstract:
Abstract Confirmatory adaptive designs comprise a range of statistical methods that allow to modify the sample size of an ongoing trial in a data-dependent way without compromising control of the type I error rate. For short-term endpoints (e.g., 3-month response rate), comprehensive methodology of adaptive designs exists. However, clinical trials in oncology often have a special focus on long-term outcome and therefore often choose a time-to-event endpoint as the primary endpoint. Typical examples are progression-free survival (PFS) or overall survival (OS). But subtle statistical problems ar
APA, Harvard, Vancouver, ISO, and other styles
7

Narayanan, Siva, Dong Shao, Anshul Shah, and Vidya Ramesh. "Use of intermediate clinical endpoints (ICE) as a primary efficacy endpoint in malignant melanoma." Journal of Clinical Oncology 35, no. 15_suppl (2017): e21075-e21075. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21075.

Full text
Abstract:
e21075 Background: Melanoma incidence in the US has seen a considerable increase, from 17.8 (1997) to 24.0 (2013) per 100,000, with localized melanoma accounting for 84% of all cases. Early detection and treatment can improve outcomes considerably, resulting in a 99% survival rate. The FDA, within its accelerated approval program, accepts ICE as a primary endpoint, shortening time for patient access to life saving medications. Our objective was to study use of ICE as a primary endpoint for therapies targeting non-metastatic/early-stage malignant melanoma. Methods: A systematic review was condu
APA, Harvard, Vancouver, ISO, and other styles
8

Mushtaq, Muhammad Umair, Moazzam Shahzad, Ezza Tariq, et al. "Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review." Blood 138, Supplement 1 (2021): 4910. http://dx.doi.org/10.1182/blood-2021-146218.

Full text
Abstract:
Abstract Background: The use of objective endpoints is critical for the generalization and clinical implications of a study. Overall survival (OS) has traditionally been used as the gold standard for demonstrating the true clinical benefit of a therapy or intervention. Use of clinically meaningful pre-specified endpoints is essential for a successful clinical trial. In this systemic review, we aimed to investigate different primary and secondary endpoints used in phase III randomized controlled trials (RCTs) for hematopoietic stem cell transplantation (HCT), and their trends over a span of 15
APA, Harvard, Vancouver, ISO, and other styles
9

Buyse, M. E., K. J. Punt, C. H. Köhne, et al. "Endpoints in adjuvant trials: A systematic review of the literature in colon cancer and proposed definitions for future trials." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4018. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4018.

Full text
Abstract:
4018 Background: Disease-free survival (DFS) is the primary endpoint of most trials testing adjuvant treatments. However many other endpoints are used. There is much confusion about these endpoints since different definitions were used among trials, or no definitions were provided at all. Moreover there is no consensus on either the definition of each endpoint or on the most relevant among these endpoints. This creates difficulties when comparing the results of various trials. Methods: Adjuvant trials in colon cancer were used as a model. A systematic review was performed on published adjuvant
APA, Harvard, Vancouver, ISO, and other styles
10

Hammel, Pascal, Ewa Carrier, Mairead Carney, Mark Eisner, and Thomas Fleming. "A novel event-free survival endpoint in locally advanced pancreatic cancer." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110595. http://dx.doi.org/10.1177/17588359211059586.

Full text
Abstract:
The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS) are presently being pursued. These efforts justify re-visiting study endpoints in order to better predict therapeutic effects on OS, by capturing not only the achievement of R0 resection at the end of induction therapy but also the long-term reductions in the rate of local and distal recurrence. The
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Survival endpoint"

1

Koh, Jeanette. "Incorporating endpoint uncertainty into biomedical survival analyses." Thesis, Koh, Jeanette (2015) Incorporating endpoint uncertainty into biomedical survival analyses. Honours thesis, Murdoch University, 2015. https://researchrepository.murdoch.edu.au/id/eprint/29985/.

Full text
Abstract:
A key problem in medical research and practice is that of accurately identifying endpoints or times-to-event in stages of disease progression or treatment outcomes. In chronic or long-term conditions such as Human Immunodeficiency Virus (HIV) infection, the reaching of the endpoint is determined by comparing an individual’s biomarker measurements over a period of time to a pre-determined threshold. The small number and irregular spacing of such measurements often make it difficult to determine when a patient has truly reached the endpoint, and current methods do not take this uncertainty into
APA, Harvard, Vancouver, ISO, and other styles
2

PACIFICO, CLAUDIA. "Comparison of propensity score based methods for estimating marginal hazard ratios with composite unweighted and weighted endpoints: simulation study and application to hepatocellular carcinoma." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2021. http://hdl.handle.net/10281/306601.

Full text
Abstract:
Introduzione La mia attività di ricerca si propone di utilizzare i dati dello studio HERCOLES, uno studio retrospettivo sull’epatocarcinoma, come esempio applicativo per il confronto di metodi statistici per la stima dell’effetto marginale di un certo trattamento su endpoint di sopravvivenza standard (non pesati) ed endpoint compositi pesati. Quest’ultimo approccio, non ancora esplorato, è motivato dalla necessità di tenere conto della diversa rilevanza clinica degli eventi causa-specifici. In particolare, la morte è considerata l'evento peggiore ma una rilevanza maggiore è data anche alla rec
APA, Harvard, Vancouver, ISO, and other styles
3

Luo, Yingchun. "Nonparametric statistical procedures for therapeutic clinical trials with survival endpoints." Thesis, Kingston, Ont. : [s.n.], 2007. http://hdl.handle.net/1974/492.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nordman, Ina IC Clinical School St Vincent's Hospital Faculty of Medicine UNSW. "Surrogate endpoints of survival in metastatic carcinoma." Publisher:University of New South Wales. Clinical School - St Vincent's Hospital, 2008. http://handle.unsw.edu.au/1959.4/42791.

Full text
Abstract:
In most randomised controlled trials (RCTs), a large number of patients need to be followed over many years, for the clinical benefit of the drug to be accurately quantified (1). Using an early proxy, or a surrogate endpoint, in place of the direct endpoint of overall survival (OS) could theoretically shorten the duration of RCTs and minimise the exposure of patients to ineffective or toxic treatments (2, 3). This thesis examined the relationship between surrogate endpoints and OS in metastatic colorectal cancer (CRC), advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (M
APA, Harvard, Vancouver, ISO, and other styles
5

Zain, Zakiyah. "Combining multiple survival endpoints within a single statistical analysis." Thesis, Lancaster University, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.618302.

Full text
Abstract:
The aim of this thesis is to develop methodology for combining multiple endpoints within a single statistical analysis that compares the responses of patients treated with a novel treatment with those of control patients treated conventionally. The focus is on interval-censored bivariate survival data, and five real data sets from previous studies concerning multiple responses are used to illustrate the techniques developed. The background to survival analysis is introduced by a general description of survival data, and an overview of existing methods and underlying models is included. A revie
APA, Harvard, Vancouver, ISO, and other styles
6

Vilakati, S. E. "Inference Following Two-Stage Randomization Designs with Survival Endpoints." Doctoral thesis, Università degli studi di Padova, 2017. http://hdl.handle.net/11577/3423158.

Full text
Abstract:
Treatment of complex diseases such as cancer, HIV, leukemia and depression usually follows complex treatment sequences. In two-stage randomization designs, patients are randomized to first-stage treatments, and upon response, a second randomization to the second-stage treatments is done. The clinical goal in such trials is to achieve a response such as complete remission of leukemia, 50% shrinkage of solid tumor or increase in CD4 count in HIV patients. These responses are presumed to predict longer survival. The focus in two-stage randomization designs with survival endpoints is on estimat
APA, Harvard, Vancouver, ISO, and other styles
7

Bofill, Roig Marta. "Statistical methods and software for clinical trials with binary and survival endpoints : efficiency, sample size and two-sample comparison." Doctoral thesis, Universitat Politècnica de Catalunya, 2020. http://hdl.handle.net/10803/670371.

Full text
Abstract:
Defining the scientific question is the starting point for any clinical study. However, even though the main objective is generally clear, how this is addressed is not usually straightforward. Clinical studies very often encompass several questions, defined as primary and secondary hypotheses, and measured through different endpoints. In clinical trials with multiple endpoints, composite endpoints, defined as the union of several endpoints, are widely used as primary endpoints. The use of composite endpoints is mainly motivated because they are expected to increase the number of observed even
APA, Harvard, Vancouver, ISO, and other styles
8

Savina, Marion. "Critères de Substitution à la Survie Globale dans les Essais Cliniques Randomisés en Cancérologie." Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0894/document.

Full text
Abstract:
Dans les essais cliniques randomisés (ECR) en cancérologie, un critère de substitution est une mesure biologique utilisée à la place d’un critère cliniquement pertinent pour le patient, par exemple la survie globale (SG), qui doit permettre de prédire l’effet attendu du traitement. Des critères alternatifs à la SG, par exemple la survie sans progression, sont de plus en plus fréquemment utilisés en tant que critère de jugement principal dans les ECR. En pratique cependant, les capacités de substitution à la SG de ces critères ne sont pas systématiquement évaluées. Nous avons dressé un état des
APA, Harvard, Vancouver, ISO, and other styles
9

Branchoux, Sébastien. "Critères de substitution de la survie globale chez les patients atteints de cancer métastatique traités par inhibiteurs de points de contrôle immunologiques." Thesis, Bordeaux, 2020. http://www.theses.fr/2020BORD0253.

Full text
Abstract:
La prise en charge du cancer au stade avancé ou métastatique a été profondément modifiée avec l’arrivée des inhibiteurs des points de contrôle immunologiques (immune-checkpoint inhibitors (ICI)). Ces anticorps monoclonaux immuno-modulateurs ont été développés pour soit déclencher une nouvelle réponse immunitaire anti-tumorale, soit réactiver une réponse existante pour lutter contre le cancer. L’espérance de vie des patients traités par ce type de thérapie est plus longue par rapport à ceux traités par les thérapies usuelles. Par conséquent, la puissance statistique requise dans un essai cliniq
APA, Harvard, Vancouver, ISO, and other styles
10

Guimarães, Bruno Miguel Machado. "MEmO: multigenerational exposure in ecotoxicological model species: effects, mechanisms and implications." Doctoral thesis, 2018. http://hdl.handle.net/10773/26168.

Full text
Abstract:
Anthropogenic pollutants are continuously released into the environment, which can result in long term exposure to soil organisms. Currently, standard guidelines focus on the assessment of effects to only one life stage, mostly juveniles, during a fixed exposure time. Additionally, these methods evaluate harmful effects of compounds to e.g. organism’s survival, reproduction and avoidance. Results obtained when testing these endpoints, even when combined, can under-/over-estimate potential damage to soil fauna. Therefore, the main aim of this thesis was to develop and explore different m
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Survival endpoint"

1

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Emura, Takeshi. Survival Analysis with Correlated Endpoints: Joint Frailty-Copula Models. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. Survival Analysis with Correlated Endpoints: Joint Frailty-Copula Models. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Emura, Takeshi, Shigeyuki Matsui, Virginie Rondeau, and Yi-Hau Chen. Survival Analysis with Dependent Censoring and Correlated Endpoints: Copula-Based Approaches. Springer Singapore Pte. Limited, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dubose, Arielle C., Benjamin D. Lee, and SreyRam Kuy. Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. Edited by SreyRam Kuy and Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0009.

Full text
Abstract:
The landmark Swedish Rectal Cancer Trial examined whether preoperative radiation given to patients <80 years of age with resectable rectal cancer impacted rate of local recurrence and survival compared with immediate surgical resection. This trial demonstrated that neoadjuvant radiation therapy decreased rates of local and distant recurrence and improved survival. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endp
APA, Harvard, Vancouver, ISO, and other styles
6

Kulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. Transplantation. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0030.

Full text
Abstract:
Organ transplantation is now a well-established therapy for patients with end-stage organ failure. Over the last 20 years, the results of transplantation have improved incrementally for many reasons, including better recipient selection, improved anaesthetic and surgical techniques, the introduction of more effective antiviral agents, and better post-transplant immunosuppressive management. The problem of early graft loss from acute rejection is now uncommon, and the main challenges today are chronic allograft rejection and the side effects of non-specific suppression of the immune response. R
APA, Harvard, Vancouver, ISO, and other styles
7

Adile, Claudio. Feeding Tube and Survival Among Patients with Severe Cognitive Impairment (DRAFT). Edited by Nathan A. Gray and Thomas W. LeBlanc. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190658618.003.0022.

Full text
Abstract:
This chapter provides an overview and commentary on the study published by Teno and colleagues in 2012 that analyzed if feeding tube insertion and its timing affect survival in patients with advanced dementia. The study concluded that insertion of feeding tubes, irrespective of the timing of insertion, does not confer a survival benefit. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism
APA, Harvard, Vancouver, ISO, and other styles
8

Kuy, SreyRam, Kai J. Yang, and Anahita Dua. Long-Term Outcomes of Immediate Repair Compared with Surveillance of Small Abdominal Aortic Aneurysm. Edited by SreyRam Kuy, Wayne Zhang, and Tze-Woei Tan. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0002.

Full text
Abstract:
This chapter provides a summary of a landmark study in vascular surgery examining whether early, prophylactic repair of small abdominal aortic aneurysm (AAA; 4.0 to 5.5 cm) improves 5-year survival. The study found that among patients with a small AAA <5.5 cm in diameter, early surgical intervention confers no survival benefit over initial surveillance. The chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, resul
APA, Harvard, Vancouver, ISO, and other styles
9

Peake, Sandra L., and Matthew J. Maiden. Management of septic shock in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0298.

Full text
Abstract:
The management of septic shock is a medical emergency. Following prompt recognition, treatment priorities are haemodynamic resuscitation, empirical antimicrobials, urgent control of the source of infection and monitoring the response to therapy. Haemodynamic resuscitation is focused on maintaining an adequate macrocirculation, while also ensuring adequacy of microcirculatory blood flow to the cells. Intravenous fluids and catecholamines have been the mainstay of therapy. However, the amount and type of fluids, choice of vasoactive medications, and the appropriate resuscitation endpoints have b
APA, Harvard, Vancouver, ISO, and other styles
10

Kwon, Rachel J. Sentinel Lymph Node Biopsy versus Nodal Observation in Melanoma. Edited by Patrick Borgen and Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0025.

Full text
Abstract:
This chapter provides a summary of a landmark study in surgical oncology. In patients with melanoma who undergo wide excision, does sentinel lymph node biopsy improve survival versus nodal observation (a “wait-and-watch” approach)? Starting with that question, it describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, disc
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Survival endpoint"

1

Chang, Mark, John Balser, Jim Roach, and Robin Bliss. "Clinical Trial with Survival Endpoint." In Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials. Chapman and Hall/CRC, 2019. http://dx.doi.org/10.1201/9781351214544-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Jianrong. "Phase II Trial Design with GMI Endpoint." In Single-Arm Phase II Survival Trial Design. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9781003129059-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ravi, Praful, and Guru P. Sonpavde. "Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints." In Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-80546-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "Introduction to Multivariate Survival Analysis." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "Personalized Dynamic Prediction of Survival." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "Setting the Scene." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "The Joint Frailty-Copula Model for Correlated Endpoints." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "High-Dimensional Covariates in the Joint Frailty-Copula Model." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Emura, Takeshi, Shigeyuki Matsui, and Virginie Rondeau. "Future Developments." In Survival Analysis with Correlated Endpoints. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3516-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Renard, Didier. "A Combination of Longitudinal and Survival Endpoints." In Statistics for Biology and Health. Springer New York, 2005. http://dx.doi.org/10.1007/0-387-27080-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Survival endpoint"

1

Harris, Wayne B., Dana C. Nickleach, Yuan Liu, Omer Kucuk, and Viraj A. Master. "Abstract C15: Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma." In Abstracts: Sixth AACR Conference: The Science of Cancer Health Disparities; December 6–9, 2013; Atlanta, GA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7755.disp13-c15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bever, Andrea, Jackie Manthorne, Tissa Rahim, Layla Moumin, Karissa Johnston, and Shelagh Szabo. "The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa2190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mattar, André, Andressa Gonçalves Amorim, Marcelo Antonini, Marina Diógenes, and Luis Henrique Gebrim. "Clinical and pathological differences between HER2 low and other cancer subtypes in breast cancer patients." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1028.

Full text
Abstract:
Objective: HER2 is a tyrosine kinase receptor belonging to the human epidermal receptor family and is considered an important proto-oncogene in the biology of breast carcinoma. HER2 overexpression is determined by a +3 score on the immunohistochemistry (IHC) assay. In addition, tumors with IHC results of +1 or +2 with ISH negative were defined as HER2-low. Recent studies have shown the clinicopathological characteristics of HER2-low tumors, pointing out potential differences regarding hormone receptor status. The objective was to assess clinicopathological differences between cancer subtypes,
APA, Harvard, Vancouver, ISO, and other styles
4

Jorge, Frederico Mennucci de Haidar, Angela Genge, Ammar Al Chalabi, et al. "MERIDIAN: A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with amyotrophic lateral sclerosis." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.744.

Full text
Abstract:
Introduction: Inflammation underlies the pathogenesis of numerous neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). In ALS, the complement system has been implicated in the neuropathology of disease and disease progression. Pegcetacoplan, a subcutaneously administered C3 complement inhibitor, is being investigated in hematology, nephrology, and neurology. The current clinical study (NCT04579666) is investigating whether pegcetacoplan can improve survival and function in people diagnosed with apparent sporadic ALS. Objectives and Methodology: Evaluate the efficacy and s
APA, Harvard, Vancouver, ISO, and other styles
5

Beronja, Branko, Olja Stevanović, Nataša Nikolić, et al. "Gender-specific mortality predictors in patients with severe COVID-19: A critical care perspective." In Proceedings of the International Congress Public Health - Achievements and Challenges. Institute of Public Health of Serbia "Dr Milan Jovanović Batut", 2024. http://dx.doi.org/10.5937/batutphco24036b.

Full text
Abstract:
Objective: The aim of this study was to assess factors associated with the risk of death in men and women individually and shed light on new aspects. Patients and methods: This retrospective cohort study was carried out at two healthcare institutions in Serbia, involving 457 patients. Patients were categorized based on their gender. The primary study endpoint was survival, specifically patient mortality. Demographic and clinical information were retrieved from electronic health records. Results: Among men, 11.4% required treatment in the intensive care unit (ICU), with a 5.7% mortality rate. M
APA, Harvard, Vancouver, ISO, and other styles
6

Overmoyer, Beth, Pedro Sanz-Altimira, Ann H. Partridge, et al. "Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-13-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Araujo, Alexandra Prufer de Queiroz Campos. "SUNFISH parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 SMA." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.507.

Full text
Abstract:
Introduction: Spinal muscular atrophy (SMA) affects individuals with a broad age range and spectrum of disease severity. Risdiplam (EVRYSDI®) is a centrally and peripherally distributed, oral survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier that has been approved in over 90 countries worldwide. SUNFISH (NCT02908685) is a multicenter, two-part, randomized, placebo-controlled, double-blind study in patients with types 2 and 3 SMA (inclusion criteria: aged 2–25 years at enrollment). Part 1 (n = 51) assessed the safety, tolerability and pharmacokinetics/pharmacodynamics of different ri
APA, Harvard, Vancouver, ISO, and other styles
8

Ahlawat, P., S. Mitra, M. K. Sharma, et al. "Comparison of the outcomes between locally advanced cervical squamous cell carcinoma and adenocarcinoma patients treated with definitive chemoradiation." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685252.

Full text
Abstract:
Objective: To present comparison of survival outcomes between locally advanced adenocarcinoma and squamous cell carcinoma patients treated with definitive chemoradiation. Methods: It is a retrospective analysis and direct comparison between adenocarcinoma and squamous cell carcinoma cervix treated from January 2011 to December 2015. Of 73 patients analyzed 61 had squamous carcinoma histology and remaining 12 had adenocarcinoma. Inclusion criteria were patients with locally advanced stage (IIA) who have completed definitive chemoradiation and were available for response evaluation at 3 months o
APA, Harvard, Vancouver, ISO, and other styles
9

Zain, Zakiyah, and John Whitehead. "Survival analysis of cancer patients with multiple endpoints using global score test methodology." In PROCEEDINGS OF THE 3RD INTERNATIONAL CONFERENCE ON MATHEMATICAL SCIENCES. AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4882621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Araújo, Danielle Cristina Miyamoto, Giuliano Mendes Duarte, Maria Beatriz de Paula Leite Kraft Enz Hubert, et al. "Sentinel lymph node biopsy versus no axillary surgery in early breast cancer clinically and ultrasonographically node-negative: A prospective randomized controlled trial – venus trial early results after 3.5 years of study inception." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1008.

Full text
Abstract:
Objective: The VENUS trial is an ongoing prospective, multi-center, non-inferiority randomized controlled clinical trial aimed at comparing the disease-free and overall survival of T1-2 N0 M0 breast cancer patients subjected to either (a) sentinel lymph node (group sentinel) or (b) no axillary surgery (group no-sentinel). This is a partial report on the initial data collected 3.5 years after the trial started. VENUS differs from previous similar trials in that women undergoing mastectomy and neoadjuvant chemotherapy are accepted. Methodology: The protocol was approved by the local research eth
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Survival endpoint"

1

Jiang, Zhiping, Ao Zhang, Shuxing Wang, Quanlei Ren, and Yizhu Wang. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.4.0013.

Full text
Abstract:
Review question / Objective: A meta-analysis was performed to investigate prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia. Condition being studied: Some MDS or AML patients have ASXL1 mutations while others haven’t. Main outcome(s): We used OS as the primary endpoint and AML transformation as the secondary endpoint. OS was defined as either death (failure) or survival at the last follow-up. AML transformation was defined as starting when the patient entered the trial and proceeding to the time of AML diagnosis.Combined HRs and 95% CIs f
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Survival endpoint' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography